VIP for CIRS and Mold Illness

Candidate profile

Adults diagnosed with chronic inflammatory response syndrome (CIRS) secondary to water-damaged building (WDB) exposure who have completed all prior steps of the Shoemaker protocol but continue to have residual symptoms or abnormal biomarkers. The candidate has been removed from ongoing biotoxin exposure (remediated home or relocated), has completed cholestyramine or welchol binding therapy, has treated MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) if present, and has addressed other correctable biomarkers per the stepwise protocol.

VIP is specifically designated as the final therapeutic step in the Shoemaker protocol. It is not a first-line intervention and should only be initiated after prerequisite conditions have been met. Patients who begin VIP before clearing MARCoNS or before removing themselves from ongoing exposure are unlikely to respond appropriately and may experience worsening of symptoms.

Understanding CIRS

Chronic inflammatory response syndrome is a multi-system, multi-symptom illness caused by exposure to biotoxins, most commonly from water-damaged buildings containing toxigenic mold species (Stachybotrys, Aspergillus, Chaetomium, Wallemia, and others), as well as actinomycetes and other microbial volatile organic compounds. The condition was characterized by Ritchie Shoemaker, MD, who developed a diagnostic and treatment framework based on innate immune dysregulation.

The pathophysiology centers on the failure of certain genetically susceptible individuals (those with specific HLA-DR haplotypes, affecting approximately 24% of the population) to properly clear biotoxins. In these individuals, biotoxins are not presented to the adaptive immune system for clearance, leading to a self-perpetuating cycle of innate immune activation. This produces a characteristic pattern of inflammatory biomarker abnormalities including elevated C4a, TGF-beta-1, and MMP-9, reduced MSH (melanocyte-stimulating hormone) and VIP, and dysregulated VEGF (vascular endothelial growth factor).

Conventional medical treatments typically fail because they address symptoms (pain, fatigue, cognitive dysfunction) rather than the underlying innate immune dysregulation. The Shoemaker protocol addresses each component of the dysregulated cascade in a specific sequential order.

What VIP is

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide (His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2) that was originally isolated from porcine intestinal tissue in 1970 by Said and Mutt. Despite its name, VIP functions far beyond the gastrointestinal tract. It is widely distributed throughout the central and peripheral nervous systems, the immune system, and the pulmonary vasculature.

VIP acts through two G-protein coupled receptors: VPAC1 (expressed on T cells, macrophages, dendritic cells, and many epithelial tissues) and VPAC2 (expressed on smooth muscle, immune cells, and the central nervous system). The binding of VIP to these receptors activates adenylyl cyclase, increasing intracellular cyclic AMP and triggering multiple downstream signaling cascades.

In CIRS patients, endogenous VIP levels are characteristically suppressed, often profoundly so. This deficiency contributes to several features of the syndrome, including pulmonary hypertension, dysregulated cytokine production, impaired regulatory T-cell function, and reduced mucosal immunity.

VIP's role in the Shoemaker protocol

The stepwise approach

The Shoemaker protocol follows a defined sequential order. Before VIP is initiated, the patient must have completed the following steps:

1. Removal from exposure -- the patient is no longer living or working in a water-damaged building
2. Cholestyramine or welchol -- bile acid sequestrant therapy to bind and eliminate circulating biotoxins
3. MARCoNS treatment -- eradication of deep nasal biofilm colonization with antibiotic nasal spray (BEG spray or equivalent), confirmed by negative API-Staph culture
4. Correction of antigliadin antibodies -- gluten-free diet if elevated
5. Correction of androgens -- DHEA and testosterone normalization if deficient
6. Correction of ADH/osmolality -- desmopressin if indicated
7. Correction of MMP-9 -- typically responds to earlier steps and dietary omega-3 supplementation
8. Correction of VEGF -- typically normalizes with earlier interventions
9. Correction of C3a -- statins if persistently elevated
10. Correction of TGF-beta-1 -- losartan if persistently elevated
11. VIP replacement -- the final step, addressing the fundamental neuropeptide deficiency

VIP is last because it will not work -- and may cause harm -- if the preceding steps have not been completed. Specifically, administering VIP to a patient with active MARCoNS colonization has been reported to worsen biofilm formation and symptoms.

Mechanism in CIRS

VIP addresses the CIRS pathophysiology through several interconnected pathways:

Regulatory T-cell induction: VIP promotes the differentiation and expansion of CD4+CD25+FoxP3+ regulatory T cells, which are critical for resolving the self-perpetuating inflammatory cycle of CIRS. These Tregs suppress the aberrant innate immune activation that drives ongoing symptoms.

Cytokine modulation: VIP shifts the cytokine milieu from pro-inflammatory to anti-inflammatory. It reduces production of TNF-alpha, IL-6, and IL-12 by activated macrophages while promoting IL-10 and TGF-beta production in the appropriate regulatory context.

Pulmonary artery pressure reduction: Many CIRS patients have elevated pulmonary artery pressures detectable by echocardiography. VIP is a potent pulmonary vasodilator and has been shown to reduce pulmonary artery systolic pressure in CIRS patients, which correlates with improvements in exercise tolerance, dyspnea, and fatigue.

MSH pathway restoration: Alpha-melanocyte-stimulating hormone (alpha-MSH) is characteristically suppressed in CIRS. VIP administration has been associated with restoration of MSH levels toward normal, which has downstream effects on cytokine regulation, appetite, sleep, and pain perception.

Protocol details

Route: Intranasal administration

Formulation: VIP must be obtained from a compounding pharmacy experienced in preparing peptide nasal sprays. The peptide is dissolved in a preservative-free sterile solution, typically at a concentration that delivers 50 mcg per spray actuation. Stability of compounded VIP preparations is limited; the solution typically requires refrigeration and has a shelf life of approximately 30-90 days depending on formulation.

Dosing: 50 mcg per nostril, 4 times daily (total daily dose of 400 mcg). Some practitioners start with lower doses (50 mcg into one nostril, 2 times daily) and titrate upward over 1-2 weeks to assess tolerance.

Duration: Treatment duration varies. Some patients require 1-3 months of VIP to normalize biomarkers and resolve symptoms, while others with more severe or longstanding CIRS may need 6-12 months or longer. Treatment is continued until clinical symptoms resolve and biomarkers normalize, then gradually tapered.

Prerequisite confirmation before starting VIP:

• Negative nasal culture for MARCoNS (absolutely required -- do not initiate VIP with positive MARCoNS)
• VIP serum level documented as low (confirms deficiency)
• Lipase within normal limits (VIP can theoretically stimulate pancreatic secretion)
• All prior Shoemaker protocol steps completed with documented biomarker improvements

Monitoring

• C4a: Should decrease toward normal range with effective VIP therapy. Measured at baseline, 1 month, and every 2-3 months thereafter.
• TGF-beta-1: Should normalize. Persistently elevated TGF-beta-1 despite VIP may indicate ongoing exposure or incomplete prior treatment steps.
• VEGF: Should move toward normal range. Both abnormally low and abnormally high VEGF are seen in CIRS; VIP tends to normalize values in either direction.
• MMP-9: Should remain suppressed. Elevation during VIP therapy warrants investigation for re-exposure or dietary triggers.
• VIP serum levels: Drawn to confirm the deficiency at baseline and to assess whether exogenous replacement is achieving adequate levels.
• MSH levels: Expected to rise toward normal with VIP treatment.
• Pulmonary function and echocardiography: Pulmonary artery pressures should be assessed at baseline and after 2-3 months of VIP. Patients with elevated baseline PASP often show measurable improvement.
• Lipase: Monitored periodically given VIP's role in pancreatic secretion. Clinically significant pancreatitis has not been reported in the CIRS literature but monitoring is prudent.
• Repeat nasal culture: MARCoNS should be retested periodically during VIP therapy to ensure colonization has not recurred.

Expected timeline

Weeks 1-2: Some patients report mild initial improvement in energy, cognitive clarity, and sleep quality within the first two weeks. Others notice transient worsening (typically mild) as immune regulation shifts.

Weeks 3-6: More consistent symptomatic improvement. Exercise tolerance typically improves. Cognitive symptoms (word-finding difficulty, poor concentration, disorientation) often show measurable improvement. Joint pain and headaches may decrease.

Months 2-4: Biomarker improvements become apparent on laboratory testing. C4a and TGF-beta-1 levels decline. VIP and MSH levels rise. Pulmonary artery pressures decrease in patients who had baseline elevation.

Months 4-12: Continued consolidation of improvements. Patients with long-standing CIRS (years of illness) typically require longer treatment courses than those with more recent onset.

Limitations and controversies

The evidence base for VIP in CIRS rests predominantly on the work of Shoemaker and colleagues, published in peer-reviewed journals but representing a relatively small body of research from a limited number of investigators. Large, multicenter, randomized controlled trials have not been conducted. The CIRS diagnostic framework itself, while clinically useful and internally consistent, remains outside mainstream medical consensus, and some of the biomarker patterns described are debated by infectious disease and allergy specialists.

Compounding quality is a significant practical concern. VIP is a delicate peptide that requires careful handling, and the potency and sterility of compounded preparations can vary between pharmacies. Patients should use pharmacies with specific experience in peptide compounding.

VIP is not FDA-approved for CIRS or any related indication. Its use in this context is off-label and based on the clinical framework developed by Shoemaker. Access to practitioners trained in the Shoemaker protocol varies by region, and insurance coverage for the requisite testing and compounded VIP is often limited.

The requirement to complete all preceding protocol steps before initiating VIP means that some patients spend months to years working through the sequential treatment before reaching this final stage. For patients with severe, debilitating symptoms, this timeline can be frustrating, but bypassing prerequisite steps has been consistently reported to produce poor outcomes.